BPC-157 Research — What the Studies Report

The current knowledge for BPC-157 is mainly derived from animal studies concerning almost exclusively from one research group located in Zagreb, Croatia, with the total of around 100 findings published on PubMed. The results gathered from studies in animals appear to be quite consistent and represent different types of tissues studied, but the fact that there are no human trials makes drawing any conclusions problematic. Below is an overview of published findings in relation to the respective research area.

The State of BPC-157 Research in 2026

Mostly Animal Models

As of October 2026, the overwhelming majority of BPC-157 studies use rats or mice. A smaller number use rabbits for musculoskeletal models. A few in vitro studies use human cell lines. No large randomized controlled trial in humans has been completed and published. This is the single most important fact about the BPC-157 evidence base.

Where the Studies Come From

Most BPC-157 publications are authored or co-authored by the Zagreb group headed by Predrag Sikiric. Other independent research groups, mostly in Taiwan, South Korea, and China, have contributed a modest and increasing number of publications. The high volume of publications produced by one group raises concerns about evidence evaluation. Independent replication is an important aspect of scientific confidence, but it is currently lacking in terms of BPC-157 studies (Seiwerth et al., 2018).

What Animal Studies Have Reported

Soft Tissue and Tendon Models

Rat and rabbit studies report that BPC-157 administration was associated with accelerated tendon healing after surgical transection. A frequently cited study in rats showed improved biomechanical properties of healing Achilles tendons compared to controls (Staresinic et al., 2003). Similar observations were reported for ligament and muscle injury models. The proposed mechanism involves upregulation of growth factors at the injury site.

Gastrointestinal Models

BPC-157 research started with studies involved in gastrointestinal studies, and this field is the one where most of the studies on this substance have been conducted. Including rat models of gastric ulcer disease, intestinal anastomosis healing, colitis, and esophageal injury. Initial Zagreb studies indicated dose-dependent protective effects of BPC-157 on gastric mucosa when given orally or intraperitoneally (Sikiric et al., 1993). Notably, BPC-157 appears to exhibit an unusual stability in the stomach when given orally, because the majority of peptides are not stable in the gastrointestinal tract.

Neurological Models

A less significant set of research explored BPC-157 in rats in terms of the dopamine and serotonin systems. The findings were the modulation of dopamine turnover and - seemingly - neuroprotective properties against drug-induced brain injuries (Sikiric et al., 2014). The research is still in its infancy and has not been duplicated by other researchers.

Cardiovascular and Vascular Models

Studies have been conducted on the use of BPC-157, particularly in models of chronic vascular impairment among rats, arterial bypass, and injuries to the blood vessels. Notably, these studies show how angiogenesis is promoted and occlusion improves post-injury (Brcic et al., 2009). It has been suggested that one of the main mechanisms responsible for the way these vascular effects occur is the nitric oxide pathway.

The Human Trial Question

What Has Been Attempted

Few publications on human beings have been found. Several publications appear to include only case studies or minor uncontrolled observations. Although one clinical trial for BPC-157 involving inflammatory bowel disease was recorded on ClinicalTrials.gov, results from the executed, extensive trial have not yet been made public. A notable gap exists between animal studies and human trials.

Why Large Trials Have Not Happened

Conducting clinical trials needs a great amount of finance, regulatory approval (through the IND application with the FDA), strict quality control during manufacturing and institutional support. BPC-157 is a research drug found in the trading gray zone, which makes the path to clinical trials rather difficult. The absence of patents for naturally occurring substances may also result in decreased interest in investment for those expensive trials from pharmaceutical companies.

How to Read a BPC-157 Study

Checking the Model (Rat vs. Human)

The first thing we check in any BPC-157 paper is the model organism. If it says "Wistar rats" or "Sprague-Dawley rats," the findings apply to rats. Translation to humans requires additional validation steps that have not been completed. We flag the species in every study we cite on this site.

Dose Scaling Problems

The rats used in BPC-157 experiments are given doses of the substance that range between 10 and 50 micrograms for every kilogram of the animal's body weight. Scaling these values up to 70-kilogram humans is not so easy. Allometric scaling factors exist, but these are only approximations, and the uncertainty is bigger for the peptides that have no data on human pharmacokinetics than for well-studied drug classes.

Funding and Conflict of Interest

The majority of studies conducted on BPC-157 do not declare commercial funding, which is a positive indicator. Nonetheless, the fact that most research comes from one particular group of researchers raises the possibility that this specific sector of research may be subject to some industrial or professional biases. In general, studies that do not produce positive outcomes are less likely to be published and this phenomenon is termed publication bias.

Limitations of the Current Evidence

Small Sample Sizes

The general number of animals used in BPC-157 trials is between 6 and 12 in each condition. This is considered a standard practice within preclinical studies, but is often not sufficient when it comes to statistical analysis. The small size of the samples raises the probability of chance or biological variability being the cause of the positive results, rather than the actual effectiveness of the drug.

Single Research Group Dominance

One of the most discussed limitations is the high number of publications involving the 'Zagreb' group. Science gains credibility by independent replication. A result repeated by several laboratories is more credible than the same result published ten times by a single laboratory. The number of independent replications of BPC-157 is increasing slow but remains inadequate.

Publication Bias

Negative published studies showing no effects of BPC-157 are rare. Hence, the published literature might be biased towards the positive outcomes. We cannot know how many studies reported negative outcomes but were never submitted for publication. This is a problem across biomedical literature, not just with BPC-157, making it relevant when analyzing the data.